PremalHarishThakerMD

Gynecologic Oncology

Professor, Obstetrics & Gynecology, David G. And Lynne Mutch Distinguished Professor, Washington University School of Medicine

Dr. Thaker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 314-362-3181

Fax+1 314-362-2893

I am an Associate Professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University in St. Louis, Missouri as well as a Clinician and a Research Member at the Siteman Cancer Center of Washington University. I trained as a cancer biologist during my fellowship at MD Anderson Cancer Center with emphasis in cell and molecular biology including angiogenesis and invasion in ovarian cancer. Now I am interested in novel therapeutics in all gynecologic cancers and have led national as well as institutional clinical trials in ovarian, cervical, and endometrial malignancies. Currently, I run our Division’s clinical trial research efforts.

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2006
University of TexasMS, Cancer Biology, 2004
University of Pennsylvania Health SystemResidency, Obstetrics and Gynecology, 1999 - 2002
Drexel University College of Medicine/Hahnemann University HospitalResidency, Obstetrics and Gynecology, 1997 - 1999
MCP-Hahnemann College of MedicineClass of 1997, MD
Villanova UniversityBA, Biology, 1995

Outstanding Publication Award for 2016 of an NRG Oncology Publication on cervical cancer in Annals of Oncology 2017
Certificate of Excellence in Reviewing Editors of Gynecologic Oncology and Gynecologic Oncology Case Reports, 2014
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

PubMed

Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1N...
Premal H Thaker, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman
International Journal of Gynecological Cancer. 2024-12-02
1 citations
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
Tullia Rushton, Harris B Krause, Timothy Samec, Andrew Elliott, Anthony N Karnezis
Gynecologic Oncology. 2024-12-01
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
Karolina A Kilowski, Martin F Dietrich, Joanne Xiu, Yasmine Baca, Andrew Hinton
Gynecologic Oncology. 2024-12-01

Journal Articles

Modified Frailty Index Is Predictive of Wound Complications in Obese Patients Undergoing Gynecologic Surgery via a Midline Vertical Incision
Premal Thaker, MD, Gynecologic Oncology
Life Stress as a Risk Factor for Sustained Anxiety and Cortisol Dysregulation During the First Year of Survivorship in Ovarian Cancer
Anil K Sood, Premal H Thaker, Laila Dahmoush, Cancer
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
Ian S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
Endometrial Carcinoma Recurrence According to Race and Ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study
M L Pearl, D S Miller, W T Creasman, P H Thaker, J F Boggess, S R Guntupalli, D G Mutch, J L Walker, O B Ioffe, D E Cohn, L S Downs, International Journal of Cancer
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
Ian S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research
Join now to see all

Celsion Corporation (NASDAQ:CLSN) Presents A Poster Highlighting Its Phase I and II OVATION 2 Clinical Trial in Advanced Ovarian Cancer with GEN-1 at A VAM on Women’s CancerApril 20th, 2021
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to Be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s CancerMarch 2nd, 2021
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging OpportunitiesAugust 9th, 2019
Join now to see all

Biobehavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance2016 - 2020
Leading Academic Participating SitesThe goal of this project is to improve patient accrual to clinical trials at NCI designated cancer centers.2014 - 2019
Gynecologic Oncology Support fundThe goal of the project is to support research in ovarian cancer targeting the identification of clinically relevant targets in ovarian cancer.2017 - 2018
Molecular Oncology Training GrantI serve as a clinical mentor to Ph.D. students in order for them to better understand how to translate bench findings in clinical problems.2005 - 2018